| Literature DB >> 9179233 |
J M De Klerk1, B A Zonnenberg, G H Blijham, A D Van Het Schip, A Hoekstra, S H Han, J M Quirijnen, A Van Dijk, P P Van Rijk.
Abstract
Recent advances in radionuclide therapy offer a new approach for the management of metastatic bone pain. This paper reports the results of dosage escalation studies with 186Re-HEDP as a bone-seeking radiopharmaceutical in patients with bone metastases originating from breast or prostate cancer with regard to toxicity, pharmacokinetics and bone marrow dosimetry and the palliating effect on bone pain. Thrombocytopenia proved to be the dose limiting factor and 186Re-HEDP showed a considerable efficacy in end-stage patients with metastatic bone pain.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9179233
Source DB: PubMed Journal: Anticancer Res ISSN： 0250-7005 Impact factor: 2.480